LysoPC(20:3)
|
Basic information |
| Metabolite name | LysoPC(20:3) |
 | N/A |
 |
C04230 |
 |
N/A |
| Synonyms | LysoPC(20:3); |
| No. of studies | 7 |
|
Basic information |
| Metabolite name | LysoPC(20:3) |
| N/A |
|
C04230 |
|
N/A |
| Synonyms | LysoPC(20:3); |
| No. of studies | 7 |
|
Relationship between LysoPC(20:3) and depression (count: 7) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Down |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M457 | Type2 | CUMS + D6 doses of PBR group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M582 | Type1 | CUMS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Up |
| Study M789 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M789 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M789 | Type2 | CUMS + liquiritin group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |